Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2007

Corgenix’ and NIH to Develop Predictive Model for Liver Fibrosis

  • Corgenix Medical entered into a corporative research and development agreement (CRADA) with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK).

    The two-year study will use Corgenix’ Hyaluronic Acid (HA) test kit alone, and in combination with other liver fibrosis biomarkers, to develop a predictive model for liver fibrosis in nonalcoholic steatohepatitis (NASH) patients. NASH patients are typically diagnosed using invasive liver biopsy procedures. The Corgenix-NIDDK study is focused on developing a noninvasive method of diagnosis.

    “This is a definitive study that will apply our HA product to an important and clearly underdiagnosed condition that affects a significant percentage of the U.S. population,” says Corgenix president and CEO Douglass Simpson. “With the rate of obesity in the U.S. continuing to increase, the prevalence of NASH will increase as well, and it will be even more important to have effective, noninvasive methods for assessment.”

    The Corgenix Hyaluronic Acid test kit has not been cleared by the FDA for in vitro diagnostic use in the U.S., but it is CE-marked for sale in the European Union.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »